Cargando…

Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation

BACKGROUND: Naturally oncolytic reovirus preferentially kills cancer cells, making it a promising cancer therapeutic. Mutations in tumour suppressor p53 are prevalent in cancers, yet the role of p53 in reovirus oncolysis is relatively unexplored. METHODS: Human cancer cell lines were exposed to Nutl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, D, Pan, L-Z, Hill, R, Marcato, P, Shmulevitz, M, Vassilev, L T, Lee, P W K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185941/ https://www.ncbi.nlm.nih.gov/pubmed/21863032 http://dx.doi.org/10.1038/bjc.2011.325

Ejemplares similares

Activation of p53 by Chemotherapeutic Agents Enhances Reovirus Oncolysis
por: Pan, Da, et al.
Publicado: (2013)

Glyoxalase I inhibition induces apoptosis in irradiated MCF-7 cells via a novel mechanism involving Hsp27, p53 and NF-κB
por: Antognelli, C, et al.
Publicado: (2014)

p63 is required beside p53 for PERP-mediated apoptosis in uveal melanoma
por: Awais, Raheela, et al.
Publicado: (2016)

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer
por: Hofstetter, G, et al.
Publicado: (2011)

The expression of p53-induced protein with death domain (Pidd) and apoptosis in oral squamous cell carcinoma
por: Bradley, G, et al.
Publicado: (2007)

Mutant p53 mediates survival of breast cancer cells
por: Lim, L Y, et al.
Publicado: (2009)

p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours
por: Dimitriadi, M, et al.
Publicado: (2008)

MiR-125b acts as an oncogene in glioblastoma cells and inhibits cell apoptosis through p53 and p38MAPK-independent pathways
por: Wu, N, et al.
Publicado: (2013)

p53 and cell cycle independent dysregulation of autophagy in chronic lymphocytic leukaemia
por: Groves, M J, et al.
Publicado: (2013)

Expression of COX-2, NF-κB-p65, NF-κB-p50 and IKKα in malignant and adjacent normal human colorectal tissue
por: Charalambous, M P, et al.
Publicado: (2009)

The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC
por: Voorneveld, P W, et al.
Publicado: (2015)

Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies
por: de Graeff, P, et al.
Publicado: (2006)

Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer
por: Kamoshida, S, et al.
Publicado: (2007)

Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma
por: Aryee, D N T, et al.
Publicado: (2013)

Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis
por: de Graeff, P, et al.
Publicado: (2009)

TIGAR induces p53-mediated cell-cycle arrest by regulation of RB–E2F1 complex
por: Madan, E, et al.
Publicado: (2012)

Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53
por: Millar, E K A, et al.
Publicado: (2011)

Mammary gland-specific ablation of focal adhesion kinase reduces the incidence of p53-mediated mammary tumour formation
por: van Miltenburg, M H A M, et al.
Publicado: (2014)

p53 immunodetection of liquid-based processed urinary samples helps to identify bladder tumours with a higher risk of progression
por: Piaton, E, et al.
Publicado: (2005)

The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodally treated squamous cell carcinoma of the oesophagus
por: Sarbia, M, et al.
Publicado: (2007)

DSC3 expression is regulated by p53, and methylation of DSC3 DNA is a prognostic marker in human colorectal cancer
por: Cui, T, et al.
Publicado: (2011)

SILAC-based phosphoproteomics reveals an inhibitory role of KSR1 in p53 transcriptional activity via modulation of DBC1
por: Zhang, H, et al.
Publicado: (2013)

Early detection of cancer in the general population: a blinded case–control study of p53 autoantibodies in colorectal cancer
por: Pedersen, J W, et al.
Publicado: (2013)

miR-1228 promotes the proliferation and metastasis of hepatoma cells through a p53 forward feedback loop
por: Zhang, Y, et al.
Publicado: (2015)

Wild-type and mutant p53 differentially regulate NADPH oxidase 4 in TGF-β-mediated migration of human lung and breast epithelial cells
por: Boudreau, H E, et al.
Publicado: (2014)

Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL
por: Meijer, A, et al.
Publicado: (2013)

Study of p53 gene alteration as a biomarker to evaluate the malignant risk of Lugol-unstained lesion with non-dysplasia in the oesophagus
por: Kaneko, K, et al.
Publicado: (2007)

Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53
por: Ou, Wen-Bin, et al.
Publicado: (2016)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

The prognostic impact of NF-κB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer
por: Al-Saad, S, et al.
Publicado: (2008)

Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor
por: Nishio, H, et al.
Publicado: (2014)

The proline TP53 variant stimulates likely lymphangiogenesis in an orthotopic mouse model of pancreatic cancer
por: Otto, N, et al.
Publicado: (2012)

MDM2 is an important prognostic and predictive factor for platin–pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53
por: Walter, R F H, et al.
Publicado: (2015)

Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway
por: Joshi, H, et al.
Publicado: (2012)

Studies on p53, BAX and Bcl-2 protein expression and microsatellite instability in stage III (UICC) colon cancer treated by adjuvant chemotherapy: major prognostic impact of proapoptotic BAX
por: Nehls, O, et al.
Publicado: (2007)

HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53
por: Meulendijks, D, et al.
Publicado: (2015)

Mutations in p53, p53 protein overexpression and breast cancer survival
por: Rossner, Pavel, et al.
Publicado: (2009)

NFκB signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression
por: McCall, P, et al.
Publicado: (2012)

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
por: Oden-Gangloff, A, et al.
Publicado: (2009)

Inhibition of constitutive and cxc-chemokine-induced NF-κB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells
por: Seaton, A, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_7tck6me544f6u9eq2uc43v22i9